-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KpCMDROQVnuCLxNLDf6gdn8v6T04MhRF6xqNd1V9EQEf1byiDPp6lGZUPBhUInrq I+z/bBHmLvhbgbDsChaDEw== 0001036050-00-000308.txt : 20000307 0001036050-00-000308.hdr.sgml : 20000307 ACCESSION NUMBER: 0001036050-00-000308 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20000303 FILED AS OF DATE: 20000303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHOENIX INTERNATIONAL LIFE SCIENCES INC CENTRAL INDEX KEY: 0000935016 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 223209631 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 6-K SEC ACT: SEC FILE NUMBER: 000-29942 FILM NUMBER: 560849 BUSINESS ADDRESS: STREET 1: 2350 COHEN STREET STREET 2: ST LAURENT QUEBEC CITY: H4R 2P7 CANADA STATE: A8 ZIP: 00000 6-K 1 FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Dated March 3, 2000 PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Translation of registrant's name into English) 2350 Cohen Street ----------------- Saint Laurent, Quebec Canada H4R 2N6 ------------------------------------ (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F X (commenced in calendar ------ ----- year 1998) Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No X ---- --- If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): -------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Registrant) Date: March 3, 2000 By: /s/ David Moszkowski ------------- ------------------------------------------------- David Moszkowski Senior Vice President and Chief Financial Officer EX-99.1 2 PRESS RELEASE Exhibit 99.1 PHOENIX INTERNATIONAL DIVESTS PRECLINICAL SERVICES UNIT IN SCRANTON, PENNSYLVANIA Montreal, March 2, 2000 - Phoenix International Life Sciences (NASDAQ: PHXI; TSE:PHX), one of the world's leading contract research organizations, today announced the sale of its Preclinical Services unit in Scranton, Pennsylvania (formerly Chrysalis Preclinical Services) to North Carolina-based Calvert Holdings Inc., a privately held company focused on providing a complete range of preclinical services. The transaction is expected to be complete within the next several weeks. "We are divesting our Scranton facility as part of our commitment to streamline previously acquired assets that are not strategic, " said Ian Lennox, Chief Executive Officer of Phoenix International. "We will continue to offer our clients a full range of toxicology and metabolism services through our facilities in Montreal and Lyon, France. This decision is consistent with our plans to consolidate operations in all service lines throughout Europe and North America." Russ McLauchlan, President and Chief Executive Officer of Calvert Holdings, commented, "We are enthusiastic about the opportunities Chrysalis Preclinical Services presents now and in the future. We selected this business for its record of high quality standards and its FDA acceptance rate in the service area we are interested in pursuing - preclinical testing in pharmacology and toxicology." Calvert Holdings has committed to long-term investment and facility enhancements that will substantially benefit the Scranton operation. ABOUT PHOENIX INTERNATIONAL Phoenix International is one of the world's leading contract research organizations. The Company is a global leader in early stage pharmaceutical development and has a growing presence in late stage pharmaceutical development. Headquartered in Montreal, Quebec, the Company employs over 2,200 people in 19 countries around the world. Phoenix International is on the worldwide web at www.pils.com. ------------ About Calvert Holdings Inc. Calvert Holdings Inc. is a newly founded management organization (incorporated in 1996) focused on providing a comprehensive range of services to the pharmaceutical and biotechnology industry. Calvert Holdings offers preclinical services in the areas of pharmacokinetics, pharmacology, formulation development, toxicology, manufacturing of clinical supplies and product and process validation. This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future revenues, earnings and growth rates and goals and operating plans of management. Phoenix's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that may cause such a difference include, but are not limited to: the inability of Phoenix to win new business at the levels required; the cancellation or delay of contracts; risks associated with the management of growth and the ability to attract and retain employees; risks of integrating newly acquired businesses; competition; any claims for patent infringement; the ability to obtain future financing; adverse regulatory developments; foreign exchange rate fluctuations; and uncertainty surrounding the Euro.
FOR MORE INFORMATION, PLEASE CONTACT: MEDIA: ANALYST CONTACT: RICHARD GAREAU DAVID MOSZKOWSKI, C.A. Director of Communications Senior V.P. and Chief Financial Officer Phoenix International Life Sciences Inc. Phoenix International Life Sciences Inc. Tel: (514) 333-0033 Tel: (514) 333-0033 Fax: (514) 335-8351 E-mail: richard.gareau@pils.com E-mail: david.moszkowski@pils.com -----------------------
CALVERT HOLDINGS: Russ McLauchlan President and Chief Executive Officer Tel.: (919) 854-4453 Fax: (919)854-2806 E-mail: rmclauchlan@calvertholdings.com -----END PRIVACY-ENHANCED MESSAGE-----